{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T01:25:17Z","timestamp":1793841917066,"version":"4.6.1"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T00:00:00Z","timestamp":1783728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"vor","delay-in-days":87,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Transl Psychiatry"],"DOI":"10.1038\/s41398-026-04191-3","type":"journal-article","created":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T12:43:54Z","timestamp":1783773834000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Brain-targeted epigenetic effects of two emerging psychoplastogens: ketamine & MDMA"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-1194-4292","authenticated-orcid":false,"given":"Moira G.","family":"Semple","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah E.","family":"Mennenga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7362-8753","authenticated-orcid":false,"given":"Ryan","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9033-3092","authenticated-orcid":false,"given":"Varun B.","family":"Dwaraka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baruch Rael","family":"Cahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Tafur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Rabin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5972-006X","authenticated-orcid":false,"given":"Berra","family":"Yazar-Klosinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Candace R.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,11]]},"reference":[{"key":"4191_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xjmad.2023.100013","volume":"2","author":"NS Udupa","year":"2023","unstructured":"Udupa NS, Twenge JM, McAllister C, Joiner TE. Increases in poor mental health, mental distress, and depression symptoms among U.S. adults, 1993\u20132020. J Mood Anxiety Disord. 2023;2:100013. https:\/\/doi.org\/10.1016\/j.xjmad.2023.100013.","journal-title":"J Mood Anxiety Disord"},{"key":"4191_CR2","unstructured":"Adolescent Mental and Behavioral Health, 2023 - National Survey of Children\u2019s Health Data Briefs - NCBI Bookshelf [Internet]. [cited 2026 Feb 11]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK608531\/"},{"key":"4191_CR3","doi-asserted-by":"publisher","first-page":"1635801","DOI":"10.3389\/fpubh.2025.1635801","volume":"13","author":"W Liu","year":"2025","unstructured":"Liu W, Zhang Y, Chen J, Li X, Huang Y, Zhao F, et al. Global burden and trends of major mental disorders in individuals under 24 years of age from 1990 to 2021, with projections to 2050: insights from the Global Burden of Disease Study 2021. Front Public Health. 2025;13:1635801. https:\/\/doi.org\/10.3389\/fpubh.2025.1635801.","journal-title":"Front Public Health"},{"key":"4191_CR4","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.3390\/ijms24021329","volume":"24","author":"A Mastinu","year":"2023","unstructured":"Mastinu A, Anyanwu M, Carone M, Abate G, Bonini SA, Peron G, et al. The bright side of psychedelics: latest advances and challenges in neuropharmacology. Int J Mol Sci. 2023;24:1329. https:\/\/doi.org\/10.3390\/ijms24021329.","journal-title":"Int J Mol Sci"},{"key":"4191_CR5","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1038\/s41591-021-01336-3","volume":"27","author":"JM Mitchell","year":"2021","unstructured":"Mitchell JM, Bogenschutz M, Lilienstein A, Harrison C, Kleiman S, Parker-Guilbert K, et al. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nat Med. 2021;27:1025\u201333. https:\/\/doi.org\/10.1038\/s41591-021-01336-3.","journal-title":"Nat Med"},{"key":"4191_CR6","doi-asserted-by":"publisher","first-page":"22","DOI":"10.36131\/cnfioritieditore20240102","volume":"21","author":"TM Almeida","year":"2024","unstructured":"Almeida TM, Lacerda da Silva UR, Pires JP, Borges IN, Martins CRM, Cordeiro Q, et al. Effectiveness of ketamine for the treatment of post-traumatic stress disorder \u2013 a systematic review and meta-analysis. Clin Neuropsychiatry. 2024;21:22\u201331. https:\/\/doi.org\/10.36131\/cnfioritieditore20240102.","journal-title":"Clin Neuropsychiatry"},{"key":"4191_CR7","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1186\/s10020-024-01013-4","volume":"30","author":"RV Lima da Cruz","year":"2024","unstructured":"Lima da Cruz RV, Le\u00e3o RN, Moulin TC. Effects of psychedelics on neurogenesis and broader neuroplasticity: a systematic review. Mol Med. 2024;30:244. https:\/\/doi.org\/10.1186\/s10020-024-01013-4.","journal-title":"Mol Med"},{"key":"4191_CR8","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1038\/s41586-025-08880-9","volume":"641","author":"EN Chung","year":"2025","unstructured":"Chung EN, Lee J, Polonio CM, Choi J, Akl CF, Kilian M, et al. Psychedelic control of neuroimmune interactions governing fear. Nature. 2025;641:1276\u201386. https:\/\/doi.org\/10.1038\/s41586-025-08880-9.","journal-title":"Nature"},{"key":"4191_CR9","doi-asserted-by":"publisher","DOI":"10.1177\/1179069518800508","volume":"12","author":"DE Olson","year":"2018","unstructured":"Olson DE. Psychoplastogens: a promising class of plasticity-promoting neurotherapeutics. J Exp Neurosci. 2018;12:1179069518800508. https:\/\/doi.org\/10.1177\/1179069518800508.","journal-title":"J Exp Neurosci"},{"key":"4191_CR10","doi-asserted-by":"publisher","first-page":"215","DOI":"10.4414\/smw.2007.11932","volume":"137","author":"JH Krystal","year":"2007","unstructured":"Krystal JH. Ketamine and the potential role for rapid-acting antidepressant medications. Swiss Med Wkly. 2007;137:215\u20136. Located at: 17525875.","journal-title":"Swiss Med Wkly"},{"key":"4191_CR11","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41386-023-01629-w","volume":"49","author":"JH Krystal","year":"2024","unstructured":"Krystal JH, Kavalali ET, Monteggia LM. Ketamine and rapid antidepressant action: new treatments and novel synaptic signaling mechanisms. Neuropsychopharmacology. 2024;49:41\u201350. https:\/\/doi.org\/10.1038\/s41386-023-01629-w.","journal-title":"Neuropsychopharmacology"},{"key":"4191_CR12","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.conb.2012.01.007","volume":"22","author":"DL Hunt","year":"2012","unstructured":"Hunt DL, Castillo PE. Synaptic plasticity of NMDA receptors: mechanisms and functional implications. Curr Opin Neurobiol. 2012;22:496\u2013508. https:\/\/doi.org\/10.1016\/j.conb.2012.01.007.","journal-title":"Curr Opin Neurobiol"},{"key":"4191_CR13","doi-asserted-by":"publisher","first-page":"749180","DOI":"10.3389\/fnbeh.2021.749180","volume":"15","author":"A Kawatake-Kuno","year":"2021","unstructured":"Kawatake-Kuno A, Murai T, Uchida S. A multiscale view of the mechanisms underlying ketamine\u2019s antidepressant effects: an update on neuronal calcium signaling. Front Behav Neurosci. 2021;15:749180. https:\/\/doi.org\/10.3389\/fnbeh.2021.749180.","journal-title":"Front Behav Neurosci"},{"key":"4191_CR14","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1038\/mp.2017.58","volume":"23","author":"I Esterlis","year":"2018","unstructured":"Esterlis I, DellaGioia N, Pietrzak RH, Matuskey D, Nabulsi N, Abdallah CG, et al. Ketamine-induced reduction in mGluR5 availability is associated with an antidepressant response: an [11C]ABP688 and PET imaging study in depression. Mol Psychiatry. 2018;23:824\u201332. https:\/\/doi.org\/10.1038\/mp.2017.58.","journal-title":"Mol Psychiatry"},{"key":"4191_CR15","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/mp.2017.190","volume":"23","author":"M Kokkinou","year":"2018","unstructured":"Kokkinou M, Ashok AH, Howes OD. The effects of ketamine on dopaminergic function: meta-analysis and review of the implications for neuropsychiatric disorders. Mol Psychiatry. 2018;23:59\u201369. https:\/\/doi.org\/10.1038\/mp.2017.190.","journal-title":"Mol Psychiatry"},{"key":"4191_CR16","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1176\/appi.ajp.2018.18020138","volume":"175","author":"NR Williams","year":"2018","unstructured":"Williams NR, Heifets BD, Blasey C, Sudheimer K, Pannu J, Pankow H, et al. Opioid receptor antagonism attenuates antidepressant effects of ketamine. Am J Psychiatry. 2018;175:1205\u201315. https:\/\/doi.org\/10.1176\/appi.ajp.2018.18020138.","journal-title":"Am J Psychiatry"},{"key":"4191_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41398-020-0844-4","volume":"10","author":"M Tiger","year":"2020","unstructured":"Tiger M, Veldman ER, Ekman CJ, Halldin C, Svenningsson P, Lundberg J. A randomized placebo-controlled PET study of ketamine\u00b4s effect on serotonin1B receptor binding in patients with SSRI-resistant depression. Transl Psychiatry. 2020;10:1\u20138. https:\/\/doi.org\/10.1038\/s41398-020-0844-4.","journal-title":"Transl Psychiatry"},{"key":"4191_CR18","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1093\/bja\/aev135","volume":"115","author":"N Khalili-Mahani","year":"2015","unstructured":"Khalili-Mahani N, Martini CH, Olofsen E, Dahan A, Niesters M. Effect of subanaesthetic ketamine on plasma and saliva cortisol secretion. Br J Anaesth. 2015;115:68\u201375. https:\/\/doi.org\/10.1093\/bja\/aev135.","journal-title":"Br J Anaesth"},{"key":"4191_CR19","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1515\/tnsci-2020-0167","volume":"12","author":"N Zhang","year":"2021","unstructured":"Zhang N, Yao L, Wang P, Liu Z. Immunoregulation and antidepressant effect of ketamine. Transl Neurosci. 2021;12:218\u201336. https:\/\/doi.org\/10.1515\/tnsci-2020-0167.","journal-title":"Transl Neurosci"},{"key":"4191_CR20","doi-asserted-by":"publisher","first-page":"e257803","DOI":"10.1001\/jamanetworkopen.2025.7803","volume":"8","author":"X Zhang","year":"2025","unstructured":"Zhang X, Hack LM, Bertrand C, Hilton R, Gray NJ, Boyar L, et al. Negative affect circuit subtypes and neural, behavioral, and affective responses to MDMA: a randomized clinical trial. JAMA Network Open. 2025;8:e257803. https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.7803.","journal-title":"JAMA Network Open"},{"key":"4191_CR21","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1038\/s41591-023-02565-4","volume":"29","author":"JM Mitchell","year":"2023","unstructured":"Mitchell JM, Ot\u2019alora GM, van der Kolk B, Shannon S, Bogenschutz M, Gelfand Y, et al. MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial. Nat Med. 2023;29:2473\u201380. https:\/\/doi.org\/10.1038\/s41591-023-02565-4.","journal-title":"Nat Med"},{"key":"4191_CR22","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1097\/00007691-200404000-00009","volume":"26","author":"R de la Torre","year":"2004","unstructured":"de la Torre R, Farr\u00e9 M, Roset PN, Pizarro N, Abanades S, Segura M, et al. Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition. Ther Drug Monit. 2004;26:137.","journal-title":"Ther Drug Monit"},{"key":"4191_CR23","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1002\/hup.348","volume":"16","author":"ME Liechti","year":"2001","unstructured":"Liechti ME, Vollenweider FX. Which neuroreceptors mediate the subjective effects of MDMA in humans? A summary of mechanistic studies. Hum Psychopharmacol. 2001;16:589\u201398. https:\/\/doi.org\/10.1002\/hup.348.","journal-title":"Hum Psychopharmacol"},{"key":"4191_CR24","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1111\/j.0019-2805.2004.01847.x","volume":"111","author":"TJ Connor","year":"2004","unstructured":"Connor TJ. Methylenedioxymethamphetamine (MDMA, \u2018Ecstasy\u2019): a stressor on the immune system. Immunology. 2004;111:357\u201367. https:\/\/doi.org\/10.1111\/j.0019-2805.2004.01847.x.","journal-title":"Immunology"},{"key":"4191_CR25","doi-asserted-by":"publisher","first-page":"3120","DOI":"10.1021\/acschemneuro.8b00590","volume":"10","author":"P Vizeli","year":"2019","unstructured":"Vizeli P, Meyer zu Schwabedissen HE, Liechti ME. Role of serotonin transporter and receptor gene variations in the acute effects of MDMA in healthy subjects. ACS Chem Neurosci. 2019;10:3120\u201331. https:\/\/doi.org\/10.1021\/acschemneuro.8b00590.","journal-title":"ACS Chem Neurosci"},{"key":"4191_CR26","doi-asserted-by":"publisher","first-page":"e250254","DOI":"10.1530\/EC-25-0254","volume":"14","author":"C Atila","year":"2025","unstructured":"Atila C, Camerin SJ, Liechti ME, Christ-Crain M. The effect of MDMA on anterior pituitary hormones: a secondary analysis of a randomized placebo-controlled trial. Endocr Connect. 2025;14:e250254. https:\/\/doi.org\/10.1530\/EC-25-0254.","journal-title":"Endocr Connect"},{"key":"4191_CR27","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1111\/biom.13307","volume":"77","author":"K Zhao","year":"2021","unstructured":"Zhao K, Oualkacha K, Lakhal-Chaieb L, Labbe A, Klein K, Ciampi A, et al. A novel statistical method for modeling covariate effects in bisulfite sequencing derived measures of DNA methylation. Biometrics. 2021;77:424\u201338. https:\/\/doi.org\/10.1111\/biom.13307.","journal-title":"Biometrics"},{"key":"4191_CR28","doi-asserted-by":"publisher","unstructured":"Zhou J, Li M, Wang X, He Y, Xia Y, Sweeney JA, et al. Drug response-related DNA methylation changes in schizophrenia, bipolar disorder, and major depressive disorder. Front Neurosci. 2021;15. https:\/\/doi.org\/10.3389\/fnins.2021.674273","DOI":"10.3389\/fnins.2021.674273"},{"key":"4191_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-019-0376-y","volume":"9","author":"PR Braun","year":"2019","unstructured":"Braun PR, Han S, Hing B, Nagahama Y, Gaul LN, Heinzman JT, et al. Genome-wide DNA methylation comparison between live human brain and peripheral tissues within individuals. Transl Psychiatry. 2019;9:47. https:\/\/doi.org\/10.1038\/s41398-019-0376-y.","journal-title":"Transl Psychiatry"},{"key":"4191_CR30","doi-asserted-by":"publisher","first-page":"892345","DOI":"10.3389\/fnmol.2022.892345","volume":"15","author":"JJ Kim","year":"2022","unstructured":"Kim JJ, Sapio MR, Vazquez FA, Maric D, Loydpierson AJ, Ma W, et al. Transcriptional activation, deactivation and rebound patterns in cortex, hippocampus and amygdala in response to ketamine infusion in rats. Front Mol Neurosci. 2022;15:892345. https:\/\/doi.org\/10.3389\/fnmol.2022.892345.","journal-title":"Front Mol Neurosci"},{"key":"4191_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2023.959590","volume":"14","author":"CR Lewis","year":"2023","unstructured":"Lewis CR, Tafur J, Spencer S, Green JM, Harrison C, Kelmendi B, et al. Pilot study suggests DNA methylation of the glucocorticoid receptor gene (NR3C1) is associated with MDMA-assisted therapy treatment response for severe PTSD. Front Psychiatry. 2023;14:959590. https:\/\/doi.org\/10.3389\/fpsyt.2023.959590.","journal-title":"Front Psychiatry"},{"key":"4191_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-025-03683-y","volume":"15","author":"KL Dawson","year":"2025","unstructured":"Dawson KL, Carangan AMJM, Klunder J, Carreras-Gallo N, Sehgal R, Megilligan S, et al. Epigenetic aging and DNA methylation biomarker changes following ketamine treatment in patients with MDD and PTSD: a pilot study. Transl Psychiatry. 2025;15:452. https:\/\/doi.org\/10.1038\/s41398-025-03683-y.","journal-title":"Transl Psychiatry"},{"key":"4191_CR33","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/s41398-025-03683-y","volume":"15","author":"K Dawson","year":"2025","unstructured":"Dawson K, Carangan AMJM, Klunder J, Carreras-Gallo N, Sehgal R, Megilligan S. et al. Ketamine treatment effects on DNA methylation and Epigenetic Biomarkers of aging. Transl Psychiatry. 2025;15:452. https:\/\/doi.org\/10.1038\/s41398-025-03683-y.","journal-title":"Transl Psychiatry"},{"key":"4191_CR34","doi-asserted-by":"publisher","first-page":"2389","DOI":"10.1038\/s41380-024-02457-0","volume":"29","author":"T Warren","year":"2024","unstructured":"Warren T, Justin T, Tyler L. Association of neurotransmitter pathway polygenic risk with specific symptom profiles in psychosis. Mol Psychiatry. 2024;29:2389\u201398. https:\/\/doi.org\/10.1038\/s41380-024-02457-0.","journal-title":"Mol Psychiatry"},{"key":"4191_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v082.i13","volume":"82","author":"A Kuznetsova","year":"2017","unstructured":"Kuznetsova A, Brockhoff PB, Christensen RHB. lmerTest package: tests in linear mixed effects models. J Stat Softw. 2017;82:1\u201326. https:\/\/doi.org\/10.18637\/jss.v082.i13.","journal-title":"J Stat Softw"},{"key":"4191_CR36","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.2217\/epi-2018-0204","volume":"11","author":"Z Zhou","year":"2019","unstructured":"Zhou Z, Lunetta KL, Smith AK, Wolf EJ, Stone A, Schichman SA, et al. Correction for multiple testing in candidate-gene methylation studies. Epigenomics. 2019;11:1089\u2013105. https:\/\/doi.org\/10.2217\/epi-2018-0204.","journal-title":"Epigenomics"},{"key":"4191_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s40345-019-0176-6","volume":"8","author":"AL Comes","year":"2020","unstructured":"Comes AL, Czamara D, Adorjan K, Anderson-Schmidt H, Andlauer TFM, Budde M, et al. The role of environmental stress and DNA methylation in the longitudinal course of bipolar disorder. Int J Bipolar Disord. 2020;8:9. https:\/\/doi.org\/10.1186\/s40345-019-0176-6.","journal-title":"Int J Bipolar Disord"},{"key":"4191_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-021-02388-x","volume":"22","author":"J Maksimovic","year":"2021","unstructured":"Maksimovic J, Oshlack A, Phipson B. Gene set enrichment analysis for genome-wide DNA methylation data. Genome Biol. 2021;22:173. https:\/\/doi.org\/10.1186\/s13059-021-02388-x.","journal-title":"Genome Biol"},{"key":"4191_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2022.104793","volume":"140","author":"M van Elk","year":"2022","unstructured":"van Elk M, Yaden DB. Pharmacological, neural, and psychological mechanisms underlying psychedelics: A critical review. Neurosci Biobehav Rev. 2022;140:104793. https:\/\/doi.org\/10.1016\/j.neubiorev.2022.104793.","journal-title":"Neurosci Biobehav Rev"},{"key":"4191_CR40","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1055\/a-1721-2914","volume":"55","author":"FX Vollenweider","year":"2022","unstructured":"Vollenweider FX, Smallridge JW. Classic psychedelic drugs: update on biological mechanisms. Pharmacopsychiatry. 2022;55:121\u201338. https:\/\/doi.org\/10.1055\/a-1721-2914.","journal-title":"Pharmacopsychiatry"},{"key":"4191_CR41","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41386-023-01666-5","volume":"49","author":"BD Heifets","year":"2024","unstructured":"Heifets BD, Olson DE. Therapeutic mechanisms of psychedelics and entactogens. Neuropsychopharmacol. 2024;49:104\u201318. https:\/\/doi.org\/10.1038\/s41386-023-01666-5.","journal-title":"Neuropsychopharmacol"},{"key":"4191_CR42","doi-asserted-by":"publisher","unstructured":"Zavaliangos-Petropulu A, Boltz T, Al-Sharif N, Taraku B, Congdon E, Espinoza R, et al. W37. CHANGES IN PERIPHERAL GENE EXPRESSION FOLLOWING ANTIDEPRESSANT KETAMINE TREATMENT. European Neuropsychopharmacology. 2023;Abstracts of the World Congress of Psychiatric Genetics (WCPG), October 10-14, 202375:S124. https:\/\/doi.org\/10.1016\/j.euroneuro.2023.08.227","DOI":"10.1016\/j.euroneuro.2023.08.227"},{"key":"4191_CR43","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41398-024-03005-8","volume":"14","author":"ASB Grice","year":"2024","unstructured":"Grice ASB, Sloofman L, Levy T, Walker H, Ganesh G, de los Santos MR. et al. Transient peripheral blood transcriptomic response to ketamine treatment in children with ADNP syndrome. Transl Psychiatry. 2024;14:307. https:\/\/doi.org\/10.1038\/s41398-024-03005-8.","journal-title":"Transl Psychiatry"},{"key":"4191_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2015.138","volume":"5","author":"MB Young","year":"2015","unstructured":"Young MB, Andero R, Ressler KJ, Howell LL. 3,4-Methylenedioxymethamphetamine facilitates fear extinction learning. Transl Psychiatry. 2015;5:e634. https:\/\/doi.org\/10.1038\/tp.2015.138.","journal-title":"Transl Psychiatry"},{"key":"4191_CR45","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1002\/cne.23048","volume":"520","author":"A Hemmerle","year":"2012","unstructured":"Hemmerle A, Dickerson J, Herring N, Schaefer T, Vorhees C, Williams M, et al. (\u00b1)3,4-Methylenedioxymethamphetamine (\u201cEcstasy\u201d) treatment modulates expression of neurotrophins and their receptors in multiple regions of adult rat brain. J Comp Neurol. 2012;520:2459\u201374. https:\/\/doi.org\/10.1002\/cne.23048.","journal-title":"J Comp Neurol"},{"key":"4191_CR46","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1111\/j.1369-1600.2010.00221.x","volume":"15","author":"F Angelucci","year":"2010","unstructured":"Angelucci F, Ricci V, Martinotti G, Palladino I, Spalletta G, Caltagirone C, et al. Ecstasy (MDMA)-addicted subjects show increased serum levels of brain-derived neurotrophic factor, independently from a rise of drug-induced psychotic symptoms. Addict Biol. 2010;15:365\u20137. https:\/\/doi.org\/10.1111\/j.1369-1600.2010.00221.x.","journal-title":"Addict Biol"},{"key":"4191_CR47","doi-asserted-by":"publisher","DOI":"10.14814\/phy2.15088","volume":"9","author":"V Rom\u00e1n","year":"2021","unstructured":"Rom\u00e1n V, Kedves R, Kelemen K, N\u00e9methy Z, Sperl\u00e1gh B, Lendvai B, et al. Contribution of analog signaling to neurotransmitter interactions and behavior: Role of transporter-mediated nonquantal dopamine release. Physiol Rep. 2021;9:e15088. https:\/\/doi.org\/10.14814\/phy2.15088.","journal-title":"Physiol Rep"},{"key":"4191_CR48","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/j.neuropharm.2008.06.062","volume":"55","author":"JW Lipton","year":"2008","unstructured":"Lipton JW, Tolod EG, Thompson VB, Pei L, Paumier KL, Terpstra BT, et al. 3,4-Methylenedioxy-N-methamphetamine (ecstasy) promotes the survival of fetal dopamine neurons in culture. Neuropharmacology. 2008;55:851\u20139. https:\/\/doi.org\/10.1016\/j.neuropharm.2008.06.062.","journal-title":"Neuropharmacology"},{"key":"4191_CR49","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.brainres.2009.08.033","volume":"1314","author":"MR Picciotto","year":"2010","unstructured":"Picciotto MR, Brabant C, Einstein EB, Kamens HM, Neugebauer NM. Effects of galanin on monoaminergic systems and HPA axis: Potential mechanisms underlying the effects of galanin on addiction- and stress-related behaviors. Brain Res. 2010;1314:206\u201318. https:\/\/doi.org\/10.1016\/j.brainres.2009.08.033.","journal-title":"Brain Res"},{"key":"4191_CR50","doi-asserted-by":"publisher","first-page":"E1666","DOI":"10.1073\/pnas.1403649111","volume":"111","author":"G Juhasz","year":"2014","unstructured":"Juhasz G, Hullam G, Eszlari N, Gonda X, Antal P, Anderson IM, et al. Brain galanin system genes interact with life stresses in depression-related phenotypes. Proc Natl Acad Sci. 2014;111:E1666\u201373. https:\/\/doi.org\/10.1073\/pnas.1403649111.","journal-title":"Proc Natl Acad Sci"},{"key":"4191_CR51","doi-asserted-by":"publisher","unstructured":"Jones PA Functions of DNA methylation: Islands, start sites, gene bodies and beyond. Nature Reviews Genetics. 2012. https:\/\/doi.org\/10.1038\/nrg3230","DOI":"10.1038\/nrg3230"},{"key":"4191_CR52","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1038\/s41580-019-0159-6","volume":"20","author":"MVC Greenberg","year":"2019","unstructured":"Greenberg MVC, Bourc\u2019his D. The diverse roles of DNA methylation in mammalian development and disease. Nat Rev Mol Cell Biol. 2019;20:590\u2013607. https:\/\/doi.org\/10.1038\/s41580-019-0159-6.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"4191_CR53","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1038\/s41588-024-01707-9","volume":"56","author":"CM Nievergelt","year":"2024","unstructured":"Nievergelt CM, Maihofer AX, Atkinson EG, Chen CY, Choi KW, Coleman JRI, et al. Genome-wide association analyses identify 95 risk loci and provide insights into the neurobiology of post-traumatic stress disorder. Nat Genet. 2024;56:792\u2013808. https:\/\/doi.org\/10.1038\/s41588-024-01707-9.","journal-title":"Nat Genet"},{"key":"4191_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101045","volume":"4","author":"S Muhie","year":"2023","unstructured":"Muhie S, Gautam A, Yang R, Misganaw B, Daigle BJ, Mellon SH, et al. Molecular signatures of post-traumatic stress disorder in war-zone-exposed veteran and active-duty soldiers. Cell Rep Med. 2023;4:101045. https:\/\/doi.org\/10.1016\/j.xcrm.2023.101045.","journal-title":"Cell Rep Med"},{"key":"4191_CR55","doi-asserted-by":"publisher","unstructured":"Maihofer A, Chen CY, Coleman J, Daskalakis N, Stein M, Ressler K, et al. INTEGRATION OF -OMICS DATA INTO PTSD GWAS PRIORITIZES 126 TARGET GENES. European Neuropsychopharmacology. 2023; Abstracts of the World Congress of Psychiatric Genetics (WCPG), October 10-14,202375:S39. https:\/\/doi.org\/10.1016\/j.euroneuro.2023.08.080","DOI":"10.1016\/j.euroneuro.2023.08.080"},{"key":"4191_CR56","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1177\/02698811211026426","volume":"35","author":"E Kopra","year":"2021","unstructured":"Kopra E, Mondelli V, Pariante C, Nikkheslat N. Ketamine\u2019s effect on inflammation and kynurenine pathway in depression: A systematic review. J Psychopharmacol. 2021;35:934\u201345. https:\/\/doi.org\/10.1177\/02698811211026426.","journal-title":"J Psychopharmacol"},{"key":"4191_CR57","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.aat.2012.12.001","volume":"50","author":"FL Liu","year":"2012","unstructured":"Liu FL, Chen TL, Chen RM. Mechanisms of ketamine-induced immunosuppression. Acta Anaesthesiologica Taiwanica. 2012;50:172\u20137. https:\/\/doi.org\/10.1016\/j.aat.2012.12.001.","journal-title":"Acta Anaesthesiologica Taiwanica"},{"key":"4191_CR58","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1038\/s41573-021-00368-1","volume":"21","author":"WC Drevets","year":"2022","unstructured":"Drevets WC, Wittenberg GM, Bullmore ET, Manji HK. Immune targets for therapeutic development in depression: towards precision medicine. Nat Rev Drug Discov. 2022;21:224\u201344. https:\/\/doi.org\/10.1038\/s41573-021-00368-1.","journal-title":"Nat Rev Drug Discov"},{"key":"4191_CR59","doi-asserted-by":"publisher","unstructured":"Lutz AK, P\u00e9rez Ar\u00e9valo A, Ioannidis V, Stirmlinger N, Demestre M, Delorme R, et al. SHANK2 mutations result in dysregulation of the ERK1\/2 pathway in human induced pluripotent stem cells-derived neurons and Shank2(\u2212\/\u2212) mice. Front Mol Neurosci. 2021;14. https:\/\/doi.org\/10.3389\/fnmol.2021.773571","DOI":"10.3389\/fnmol.2021.773571"},{"key":"4191_CR60","doi-asserted-by":"publisher","first-page":"14134","DOI":"10.1523\/JNEUROSCI.1711-10.2010","volume":"30","author":"D Oh","year":"2010","unstructured":"Oh D, Han S, Seo J, Lee JR, Choi J, Groffen J, et al. Regulation of synaptic Rac1 activity, long-term potentiation maintenance, and learning and memory by BCR and ABR Rac GTPase-activating proteins. J Neurosci. 2010;30:14134\u201344. https:\/\/doi.org\/10.1523\/JNEUROSCI.1711-10.2010.","journal-title":"J Neurosci"},{"key":"4191_CR61","doi-asserted-by":"publisher","first-page":"e92052","DOI":"10.1172\/jci.insight.92052","volume":"2","author":"AL Pappas","year":"2017","unstructured":"Pappas AL, Bey AL, Wang X, Rossi M, Kim YH, Yan H, et al. Deficiency of Shank2 causes mania-like behavior that responds to mood stabilizers. JCI Insight. 2017;2:e92052. https:\/\/doi.org\/10.1172\/jci.insight.92052.","journal-title":"JCI Insight"},{"key":"4191_CR62","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1038\/s41386-022-01277-6","volume":"47","author":"S Griesius","year":"2022","unstructured":"Griesius S, O\u2019Donnell C, Waldron S, Thomas KL, Dwyer DM, Wilkinson LS, et al. Reduced expression of the psychiatric risk gene DLG2 (PSD93) impairs hippocampal synaptic integration and plasticity. Neuropsychopharmacol. 2022;47:1367\u201378. https:\/\/doi.org\/10.1038\/s41386-022-01277-6.","journal-title":"Neuropsychopharmacol"},{"key":"4191_CR63","doi-asserted-by":"publisher","first-page":"3537","DOI":"10.3390\/ijms20143537","volume":"20","author":"A Andrade","year":"2019","unstructured":"Andrade A, Brennecke A, Mallat S, Brown J, Gomez-Rivadeneira J, Czepiel N, et al. Genetic associations between voltage-gated calcium channels and psychiatric disorders. Int J Mol Sci. 2019;20:3537. https:\/\/doi.org\/10.3390\/ijms20143537.","journal-title":"Int J Mol Sci"},{"key":"4191_CR64","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1038\/s41380-019-0426-0","volume":"24","author":"VS Sohal","year":"2019","unstructured":"Sohal VS, Rubenstein JLR. Excitation-inhibition balance as a framework for investigating mechanisms in neuropsychiatric disorders. Mol Psychiatry. 2019;24:1248\u201357. https:\/\/doi.org\/10.1038\/s41380-019-0426-0.","journal-title":"Mol Psychiatry"},{"key":"4191_CR65","doi-asserted-by":"publisher","DOI":"10.1093\/oons\/kvac011","volume":"1","author":"VD Bhat","year":"2022","unstructured":"Bhat VD, Jayaraj J, Babu K. RNA and neuronal function: the importance of post-transcriptional regulation. Oxf Open Neurosci. 2022;1:kvac011. https:\/\/doi.org\/10.1093\/oons\/kvac011.","journal-title":"Oxf Open Neurosci"},{"key":"4191_CR66","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpsgos.2024.100421","volume":"5","author":"T Hanson","year":"2025","unstructured":"Hanson T, Spencer S, Harker SA, Barry F, Burton P, Beauchemin J, et al. Peripheral DNA methylation of cortisol- and serotonin-related genes predicts hippocampal volume in a pediatric population. Biol Psychiatry Glob Open Sci. 2025;5:100421. https:\/\/doi.org\/10.1016\/j.bpsgos.2024.100421.","journal-title":"Biol Psychiatry Glob Open Sci"},{"key":"4191_CR67","doi-asserted-by":"publisher","unstructured":"Spencer S, Harker SA, Barry F, Beauchemin J, Braden BB, Burton P, et al. The peripheral epigenome predicts white matter volume contingent on developmental stage: An ECHO study. Res Sq. 2024;rs.3.rs-4139933. https:\/\/doi.org\/10.21203\/rs.3.rs-4139933\/v1","DOI":"10.21203\/rs.3.rs-4139933\/v1"},{"key":"4191_CR68","doi-asserted-by":"publisher","first-page":"2839","DOI":"10.1038\/s41380-023-02067-2","volume":"28","author":"E Walton","year":"2023","unstructured":"Walton E, Baltramonaityte V, Calhoun V, Heijmans BT, Thompson PM, Cecil CAM. A systematic review of neuroimaging epigenetic research: calling for an increased focus on development. Mol Psychiatry. 2023;28:2839\u201347. https:\/\/doi.org\/10.1038\/s41380-023-02067-2.","journal-title":"Mol Psychiatry"},{"key":"4191_CR69","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1007\/s43440-023-00539-4","volume":"75","author":"A Ws\u00f3\u0142","year":"2023","unstructured":"Ws\u00f3\u0142 A. Cardiovascular safety of psychedelic medicine: current status and future directions. Pharmacol Rep. 2023;75:1362\u201380. https:\/\/doi.org\/10.1007\/s43440-023-00539-4.","journal-title":"Pharmacol Rep"},{"key":"4191_CR70","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1111\/bph.15977","volume":"180","author":"A Inserra","year":"2023","unstructured":"Inserra A, Giorgini G, Lacroix S, Bertazzo A, Choo J, Markopolous A, et al. Effects of repeated lysergic acid diethylamide (LSD) on the mouse brain endocannabinoidome and gut microbiome. Br J Pharmacol. 2023;180:721\u201339. https:\/\/doi.org\/10.1111\/bph.15977.","journal-title":"Br J Pharmacol"}],"container-title":["Translational Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41398-026-04191-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-026-04191-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-026-04191-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T02:46:53Z","timestamp":1791254813000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41398-026-04191-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,11]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4191"],"URL":"https:\/\/doi.org\/10.1038\/s41398-026-04191-3","relation":{},"ISSN":["2158-3188"],"issn-type":[{"value":"2158-3188","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,11]]},"assertion":[{"value":"25 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Conflicts of interest: BY-K received payment for full-time employment from the MAPS or the MAPS Public Benefit Corporation or Lykos Therapeutics throughout her work on the parent trial. JT is the Executive Director of Modern Spirit, a non-profit organization that contributed funds for the MDMA analyses study. BC is on the Board of Directors for Modern Spirit. BC is on the Board of Directors for Modern Spirit. DR is the Executive Director of Board of Medicine, a non-profit organization that contributed funds for the MDMA analyses study. RS and VD are paid employees of TruDiagnostic.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"All methods were performed in accordance with the relevant guidelines and regulations. The ketamine study (Dawson et al., 2025) was approved by the Institutional Review Board of the Institute of Regenerative and Cellular Medicine (Approval No. IRCM-2022-320; ClinicalTrials.gov: NCT05294835). The MDMA study (Mitchell et al., 2021) was a multi-site Phase 3 clinical trial (ClinicalTrials.gov: NCT03537014) conducted in accordance with the principles of the Declaration of Helsinki; ethics approval was obtained from the Copernicus Group Independent Review Board, the Western Institutional Review Board, the University of British Columbia Providence Healthcare Research Ethics Board, and the Helsinki Committees of Be\u2019er Ya\u2019akov Ness Ziona Mental Health Center and Chaim Sheba Medical Center. Informed consent was obtained from all participants prior to enrollment in each respective parent trial. No identifiable human images are presented in this manuscript.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"524"}}